Donald J F
J Int Med Res. 1979;7(6):502-6. doi: 10.1177/030006057900700604.
A multicentre, double-blind, crossover study monitoring walking distance and symptomatology was set up to compare the efficacy of cinnarizine with that of placebo in the treatment of patients with intermittent claudication. Walking distances were statistically significantly increased by cinnarizine treatment when it was given before placebo. This improvement was maintained without further significant deterioration when the patients were switched to placebo therapy. A smaller but statistically significant increase in walking distance was observed after the first 12 weeks of tarizine treatment an additional increase in mean walking distance, comparable to that seen during the first half of the study, was observed in these subjects. This improvement failed to reach a level of statistical significance because of the variation in response between individual patients.
开展了一项多中心、双盲、交叉研究，监测步行距离和症状，以比较桂利嗪与安慰剂治疗间歇性跛行患者的疗效。当在给予安慰剂之前给予桂利嗪治疗时，步行距离在统计学上显著增加。当患者改用安慰剂治疗时，这种改善得以维持，且未进一步显著恶化。在给予桂利嗪治疗的前12周后，观察到步行距离有较小但在统计学上显著的增加；在这些受试者中，观察到平均步行距离有额外增加，与研究前半段观察到的增加相当。由于个体患者反应的差异，这种改善未达到统计学显著水平。
